Published On : March 2024 Email: help@24marketreports.com Global Hepatocellular Carcinoma Targeted Drug Market Research Report 2024(Status and Outlook)
Report Studies
• The Global Hepatocellular Carcinoma Targeted Drug Market Size was estimated at USD 914.92 million in 2023 and is projected to reach USD 1435.81 million by 2029, exhibiting a CAGR of 7.80% during the forecast period.
• The most effective targeted drug introduced for HCC has beensorafenib. Sorafenib, a multi-tyrosine kinase inhibitor (TKI), remains the only systemic targeted tumor therapy in use for advanced HCC (18-21).
Email: help@24marketreports.com Call: +1(646)-781-7170 (Int'l)
Email: help@24marketreports.com Call: +1(646)-781-7170 (Int'l) By Types Sorafenib Lenvatinib Regorafeni b Other
Email: help@24marketreports.com Call: +1(646)-781-7170 (Int'l) By Applications • Hospital • Retail Pharmacy • Other $0 $10,000 $20,000 $30,000 $40,000 $50,000 $0 $5,000 $10,000 $15,000 $20,000 $25,000 $30,000 $35,000
©All Rights Reserved, 24 Market Reports +1(646)-781-7170 (Int'l) Get in touch E-mail: help@24marketreports.com Call : +91 8087042414 (Asia) Call : www.24marketreports.com URL: Full Report URL: https://www.24marketreports.com/life-sciences/global-hepatocellularcarcinoma-targeted-drug-2024-596